Opioid Use Disorder Oud Market
PUBLISHED: 2023 ID: SMRC22653
SHARE
SHARE

Opioid Use Disorder Oud Market

Opioid Use Disorder (OUD) Market Forecasts to 2028 - Global Analysis By Drug Class (Methadone, Naltrexone and Buprenorphine), Distribution Channel (Retail Pharmacies & Stores, Hospitals Pharmacies and Online Pharmacies), Route of Administration (Parenteral and Oral), Age group (19 to 39, 40 to 59 and Age 60 and over), and By Geography

4.4 (77 reviews)
4.4 (77 reviews)
Published: 2023 ID: SMRC22653

This report covers the impact of COVID-19 on this global market
Loading...

Years Covered

2020-2028

Estimated Year Value (2022)

US $3.17 BN

Projected Year Value (2028)

US $6.79 BN

CAGR (2022 - 2028)

13.5%

Regions Covered

North America, Europe, Asia Pacific, South America, and Middle East & Africa

Countries Covered

US, Canada, Mexico, Germany, UK, Italy, France, Spain, Japan, China, India, Australia, New Zealand, South Korea, Rest of Asia Pacific, South America, Argentina, Brazil, Chile, Middle East & Africa, Saudi Arabia, UAE, Qatar, and South Africa

Largest Market

Asia Pacific

Highest Growing Market

North America


According to Stratistics MRC, the Global Opioid Use Disorder (OUD) Market is accounted for $3.17 billion in 2022 and is expected to reach $6.79 billion by 2028 growing at a CAGR of 13.5% during the forecast period. Opioids are a class of medications that also relax muscles, lessen pain, and ease stress. To treat moderate to severe pain, doctors often prescribe drugs like hydrocodone, oxycodone, codeine, fentanyl, methadone, morphine, and other prescription opioids. It involves functional alterations to brain circuits associated to motivation, stress, self-control, and decision-making, and because those changes may persist for a long time after drug use has stopped, it is recognised as a brain condition.



Market Dynamics:

Driver:

Growing focus of government & non-government institutions to support expansion

The expansion of the business is being fuelled in part by the growing involvement of governmental and non-governmental organisations in raising awareness of opioid overdose and associated consequences. Several groups have expanded their efforts to combat the issue as a result of the sharp rise in the number of opioid addicts. In order to help patients and decrease the effects of opioid dependence, many countries have increased their efforts. For instance, Health and Human Services (HHS) announced financing for substance use treatment and prevention programmes in order to increase access to medication-assisted treatment for opioid use disorder and curb prescription drug abuse. It is predicted that similar programmes would motivate more people with opioid-related problems to seek treatment.

Restraint:

Adverse effects of OUD drugs

The market is expected to experience challenges throughout the forecast period due to the negative effects of the medications used to treat opioid addiction. These medications frequently cause muscle aches, nausea, vomiting, diarrhoea, bone or joint pain, respiratory problems, bladder pain, constipation, and cramping in the abdomen. In addition, in extreme instances of a medication reaction, the patient may also experience depression and other psychological issues. The U.S. FDA issued a warning due to the hazards involved with these medications, which has a negative effect on the drug class and decreases the use of medications for this type of treatment.

Opportunity:

Increasing consideration of buprenorphine patches

An increase in demand for buprenorphine patch treatments has lately been observed in the market. These patches are regarded as an effective medication for the treatment of opioid use disorders. Transdermal patches have a number of traditional, self-administered benefits, including an easier drug administration mechanism and less pain. Also, these transdermal patches might be a viable substitute for patients who need 24/7 opioid medication for opioid use disorder. Also, it is predicted that during the forecast period, a growing number of new patients will contribute to the growth of the global market for opioid use disorder (OUD).

Threat:

Effects withdrawal syndrome

Withdrawal syndrome, which develops when repeated exposure to a pharmaceutical stimulus is stopped, is linked to dependency. Patients should be warned not to stop using long-term opioids without first lowering their dosage. Substance use disorder's subcategory of dependency can show physical, psychological, or both signs and symptoms. Regardless of the type of opioid used, withdrawal symptoms usually begin around the time of dependence. The main issue with opioid use disorder is withdrawal. When compared to methadone, withdrawal from heroin might start as quickly as five hours following the last dose. Withdrawal symptoms that last for days or weeks are referred to as prolonged abstinence syndrome.

Covid-19 Impact

Due to demand, the coronavirus pandemic has a variety of effects on the pharmaceutical business, ranging from favourable to unfavourable. Because fewer people are visiting healthcare institutions like hospitals and clinics, there has been a detrimental effect on the demand for some medications. Furthermore, a handful of governments have implemented a rigorous nationwide lockdown in an effort to reduce the number of coronavirus cases. This has caused the flow of patients between hospital settings to drastically decrease. Moreover, the cancellation or delay of unnecessary medical treatments has had a detrimental effect on market expansion. However, throughout the pandemic, well-known companies operating in the market for opioid use disorders, including Indivior PLC, saw a general reduction in their product revenues. As a result of COVID-19-related disruptions including lockdowns, transportation problems, and others, sales have fallen down quickly. Thus, it is anticipated that the market for opioid use disorders will suffer a setback.

The buprenorphine segment is expected to be the largest during the forecast period

The buprenorphine segment is estimated to have a lucrative growth. The most frequently recommended medications for OUD are buprenorphine/naloxone sublingual pills, buprenorphine sublingual tablets, and brand-name Suboxone. Because to its outstanding clinical profile, Suboxone Film is the medication that doctors most frequently prescribe in the OUD market. The high acceptance of this medicine can be due to a number of variables, including its good formulary coverage, high efficacy in controlling addiction, low potential for abuse, and very minor adverse effects.

The parenteral segment is expected to have the highest CAGR during the forecast period

The parenteral segment is anticipated to witness the fastest CAGR growth during the forecast period, due to the availability of several OUD medications in parenteral form and a range of dosages. As a result, this method of drug administration continues to rule the world market.

Region with highest share:

Asia Pacific is projected to hold the largest market share during the forecast period owing to increasing awareness amongst the general population regarding OUD. Additionally, the substantial patient population base and the increasing healthcare spending in the region are likely to favour the growth of the market in the region.

Region with highest CAGR:

North America is projected to have the highest CAGR over the forecast period. One of the major drivers behind North America's largest market share is the opioid epidemic that has ravaged the United States and Canada due to the governments are implementing a number of initiatives. For instance, the American government started a public awareness campaign to fight opioid addiction. Throughout the course of the projected year, new medications are also anticipated to enter the U.S. market, including Braeburn's CAM-2038-additional buprenorphine subcutaneous formulation for regular monthly injection.



Key players in the market

Some of the key players profiled in the Opioid Use Disorder (OUD) Market include Alkermes, Titan Pharmaceuticals, Inc, Hikma Pharmaceuticals PLC, Indivior PLC, Mallinckrodt Pharmaceuticals, Camurus, Orexo AB, Viatris Inc, BioDelivery Sciences International Inc., Teva Pharmaceuticals Usa, Inc, Mylan, Azanta, Braeburn, Chiesi Pharmaceuticals, DiaMo Narcotics, MaynePharma Group, Knight Therapeutics, Dr. Reddy's Laboratories, Collegium Pharmaceutical, Inc and Buvidal.

Key Developments:

In March 2022, Collegium Pharmaceutical, Inc. announced that it had completed the acquisition of BioDelivery Sciences International Inc.

In June 2020, Titan Pharmaceuticals, Inc. entered into a partnership with Indegene to establish a multichannel digital marketing program throughout the U.S. and further increase their competence in providing Probuphine implant 2016 for opioid addiction patients.

In February 2021, Orexo AB announced its collaboration with ApexB.io and Magellan Rx Management to further research the use of Modia. This product is a digital therapeutic designed for patients with Opioid Use Disorder.

In December 2020, Orexo AB entered into an exclusive agreement with Accord Healthcare for the commercialization of ZUBSOLV and naloxone sublingual tablets in Europe.

In February 2019, Dr. Reddy's Laboratories announced the re-launch of its buprenorphine and naloxone sublingual film after the company received a favourable ruling in patent litigation.

Drug Classes Covered:
• Methadone
• Naltrexone
• Buprenorphine

Distribution Channels Covered:
• Retail Pharmacies & Stores
• Hospitals Pharmacies
• Online Pharmacies

Route of Administrations Covered:
• Parenteral
• Oral

Age groups Covered:
• 19 to 39
• 40 to 59
• Age 60 and over

Regions Covered:
• North America
o US
o Canada
o Mexico
• Europe
o Germany
o UK
o Italy
o France
o Spain
o Rest of Europe
• Asia Pacific
o Japan
o China
o India
o Australia
o New Zealand
o South Korea
o Rest of Asia Pacific
• South America
o Argentina
o Brazil
o Chile
o Rest of South America
• Middle East & Africa
o Saudi Arabia
o UAE
o Qatar
o South Africa
o Rest of Middle East & Africa

What our report offers:
- Market share assessments for the regional and country-level segments
- Strategic recommendations for the new entrants
- Covers Market data for the years 2020, 2021, 2022, 2025, and 2028
- Market Trends (Drivers, Constraints, Opportunities, Threats, Challenges, Investment Opportunities, and recommendations)
- Strategic recommendations in key business segments based on the market estimations
- Competitive landscaping mapping the key common trends
- Company profiling with detailed strategies, financials, and recent developments
- Supply chain trends mapping the latest technological advancements

Free Customization Offerings:
All the customers of this report will be entitled to receive one of the following free customization options:
• Company Profiling
o Comprehensive profiling of additional market players (up to 3)
o SWOT Analysis of key players (up to 3)
• Regional Segmentation
o Market estimations, Forecasts and CAGR of any prominent country as per the client's interest (Note: Depends on feasibility check)
• Competitive Benchmarking
o Benchmarking of key players based on product portfolio, geographical presence, and strategic alliances

Table of Contents

1 Executive Summary

2 Preface
2.1 Abstract
2.2 Stake Holders
2.3 Research Scope
2.4 Research Methodology
2.4.1 Data Mining
2.4.2 Data Analysis
2.4.3 Data Validation
2.4.4 Research Approach
2.5 Research Sources
2.5.1 Primary Research Sources
2.5.2 Secondary Research Sources
2.5.3 Assumptions

3 Market Trend Analysis
3.1 Introduction
3.2 Drivers
3.3 Restraints
3.4 Opportunities
3.5 Threats
3.6 Emerging Markets
3.7 Impact of Covid-19

4 Porters Five Force Analysis
4.1 Bargaining power of suppliers
4.2 Bargaining power of buyers
4.3 Threat of substitutes
4.4 Threat of new entrants
4.5 Competitive rivalry

5 Global Opioid Use Disorder (OUD) Market, By Drug Class
5.1 Introduction
5.2 Methadone
5.3 Naltrexone
5.4 Buprenorphine
5.4.1 Bunavail
5.4.2 Sublocade
5.4.3 Suboxone
5.4.4 Zubsolv

6 Global Opioid Use Disorder (OUD) Market, By Distribution Channel
6.1 Introduction
6.2 Retail Pharmacies & Stores
6.3 Hospitals Pharmacies
6.4 Online Pharmacies

7 Global Opioid Use Disorder (OUD) Market, By Route of Administration
7.1 Introduction
7.2 Parenteral
7.3 Oral

8 Global Opioid Use Disorder (OUD) Market, By Age group
8.1 Introduction
8.2 19 to 39
8.3 40 to 59
8.4 Age 60 and over

9 Global Opioid Use Disorder (OUD) Market, By Geography
9.1 Introduction
9.2 North America
9.2.1 US
9.2.2 Canada
9.2.3 Mexico
9.3 Europe
9.3.1 Germany
9.3.2 UK
9.3.3 Italy
9.3.4 France
9.3.5 Spain
9.3.6 Rest of Europe
9.4 Asia Pacific
9.4.1 Japan
9.4.2 China
9.4.3 India
9.4.4 Australia
9.4.5 New Zealand
9.4.6 South Korea
9.4.7 Rest of Asia Pacific
9.5 South America
9.5.1 Argentina
9.5.2 Brazil
9.5.3 Chile
9.5.4 Rest of South America
9.6 Middle East & Africa
9.6.1 Saudi Arabia
9.6.2 UAE
9.6.3 Qatar
9.6.4 South Africa
9.6.5 Rest of Middle East & Africa

10 Key Developments
10.1 Agreements, Partnerships, Collaborations and Joint Ventures
10.2 Acquisitions & Mergers
10.3 New Product Launch
10.4 Expansions
10.5 Other Key Strategies

11 Company Profiling
11.1 Alkermes
11.2 Titan Pharmaceuticals, Inc
11.3 Hikma Pharmaceuticals PLC
11.4 Indivior PLC
11.5 Mallinckrodt Pharmaceuticals
11.6 Camurus
11.7 Orexo AB
11.8 Viatris Inc
11.9 BioDelivery Sciences International Inc.
11.10 Teva Pharmaceuticals Usa, Inc
11.11 Mylan
11.12 Azanta
11.13 Braeburn
11.14 Chiesi Pharmaceuticals
11.15 DiaMo Narcotics
11.16 MaynePharma Group
11.17 Knight Therapeutics
11.18 Dr. Reddy's Laboratories
11.19 Collegium Pharmaceutical, Inc
11.20 Buvidal

List of Tables
1 Global Opioid Use Disorder (OUD) Market Outlook, By Region (2020-2028) ($MN)
2 Global Opioid Use Disorder (OUD) Market Outlook, By Drug Class (2020-2028) ($MN)
3 Global Opioid Use Disorder (OUD) Market Outlook, By Methadone (2020-2028) ($MN)
4 Global Opioid Use Disorder (OUD) Market Outlook, By Naltrexone (2020-2028) ($MN)
5 Global Opioid Use Disorder (OUD) Market Outlook, By Buprenorphine (2020-2028) ($MN)
6 Global Opioid Use Disorder (OUD) Market Outlook, By Bunavail (2020-2028) ($MN)
7 Global Opioid Use Disorder (OUD) Market Outlook, By Sublocade (2020-2028) ($MN)
8 Global Opioid Use Disorder (OUD) Market Outlook, By Suboxone (2020-2028) ($MN)
9 Global Opioid Use Disorder (OUD) Market Outlook, By Zubsolv (2020-2028) ($MN)
10 Global Opioid Use Disorder (OUD) Market Outlook, By Distribution Channel (2020-2028) ($MN)
11 Global Opioid Use Disorder (OUD) Market Outlook, By Retail Pharmacies & Stores (2020-2028) ($MN)
12 Global Opioid Use Disorder (OUD) Market Outlook, By Hospitals Pharmacies (2020-2028) ($MN)
13 Global Opioid Use Disorder (OUD) Market Outlook, By Online Pharmacies (2020-2028) ($MN)
14 Global Opioid Use Disorder (OUD) Market Outlook, By Route of Administration (2020-2028) ($MN)
15 Global Opioid Use Disorder (OUD) Market Outlook, By Parenteral (2020-2028) ($MN)
16 Global Opioid Use Disorder (OUD) Market Outlook, By Oral (2020-2028) ($MN)
17 Global Opioid Use Disorder (OUD) Market Outlook, By Age group (2020-2028) ($MN)
18 Global Opioid Use Disorder (OUD) Market Outlook, By 19 to 39 (2020-2028) ($MN)
19 Global Opioid Use Disorder (OUD) Market Outlook, By 40 to 59 (2020-2028) ($MN)
20 Global Opioid Use Disorder (OUD) Market Outlook, By Age 60 and over (2020-2028) ($MN)
21 North America Opioid Use Disorder (OUD) Market Outlook, By Country (2020-2028) ($MN)
22 North America Opioid Use Disorder (OUD) Market Outlook, By Drug Class (2020-2028) ($MN)
23 North America Opioid Use Disorder (OUD) Market Outlook, By Methadone (2020-2028) ($MN)
24 North America Opioid Use Disorder (OUD) Market Outlook, By Naltrexone (2020-2028) ($MN)
25 North America Opioid Use Disorder (OUD) Market Outlook, By Buprenorphine (2020-2028) ($MN)
26 North America Opioid Use Disorder (OUD) Market Outlook, By Bunavail (2020-2028) ($MN)
27 North America Opioid Use Disorder (OUD) Market Outlook, By Sublocade (2020-2028) ($MN)
28 North America Opioid Use Disorder (OUD) Market Outlook, By Suboxone (2020-2028) ($MN)
29 North America Opioid Use Disorder (OUD) Market Outlook, By Zubsolv (2020-2028) ($MN)
30 North America Opioid Use Disorder (OUD) Market Outlook, By Distribution Channel (2020-2028) ($MN)
31 North America Opioid Use Disorder (OUD) Market Outlook, By Retail Pharmacies & Stores (2020-2028) ($MN)
32 North America Opioid Use Disorder (OUD) Market Outlook, By Hospitals Pharmacies (2020-2028) ($MN)
33 North America Opioid Use Disorder (OUD) Market Outlook, By Online Pharmacies (2020-2028) ($MN)
34 North America Opioid Use Disorder (OUD) Market Outlook, By Route of Administration (2020-2028) ($MN)
35 North America Opioid Use Disorder (OUD) Market Outlook, By Parenteral (2020-2028) ($MN)
36 North America Opioid Use Disorder (OUD) Market Outlook, By Oral (2020-2028) ($MN)
37 North America Opioid Use Disorder (OUD) Market Outlook, By Age group (2020-2028) ($MN)
38 North America Opioid Use Disorder (OUD) Market Outlook, By 19 to 39 (2020-2028) ($MN)
39 North America Opioid Use Disorder (OUD) Market Outlook, By 40 to 59 (2020-2028) ($MN)
40 North America Opioid Use Disorder (OUD) Market Outlook, By Age 60 and over (2020-2028) ($MN)
41 Europe Opioid Use Disorder (OUD) Market Outlook, By Country (2020-2028) ($MN)
42 Europe Opioid Use Disorder (OUD) Market Outlook, By Drug Class (2020-2028) ($MN)
43 Europe Opioid Use Disorder (OUD) Market Outlook, By Methadone (2020-2028) ($MN)
44 Europe Opioid Use Disorder (OUD) Market Outlook, By Naltrexone (2020-2028) ($MN)
45 Europe Opioid Use Disorder (OUD) Market Outlook, By Buprenorphine (2020-2028) ($MN)
46 Europe Opioid Use Disorder (OUD) Market Outlook, By Bunavail (2020-2028) ($MN)
47 Europe Opioid Use Disorder (OUD) Market Outlook, By Sublocade (2020-2028) ($MN)
48 Europe Opioid Use Disorder (OUD) Market Outlook, By Suboxone (2020-2028) ($MN)
49 Europe Opioid Use Disorder (OUD) Market Outlook, By Zubsolv (2020-2028) ($MN)
50 Europe Opioid Use Disorder (OUD) Market Outlook, By Distribution Channel (2020-2028) ($MN)
51 Europe Opioid Use Disorder (OUD) Market Outlook, By Retail Pharmacies & Stores (2020-2028) ($MN)
52 Europe Opioid Use Disorder (OUD) Market Outlook, By Hospitals Pharmacies (2020-2028) ($MN)
53 Europe Opioid Use Disorder (OUD) Market Outlook, By Online Pharmacies (2020-2028) ($MN)
54 Europe Opioid Use Disorder (OUD) Market Outlook, By Route of Administration (2020-2028) ($MN)
55 Europe Opioid Use Disorder (OUD) Market Outlook, By Parenteral (2020-2028) ($MN)
56 Europe Opioid Use Disorder (OUD) Market Outlook, By Oral (2020-2028) ($MN)
57 Europe Opioid Use Disorder (OUD) Market Outlook, By Age group (2020-2028) ($MN)
58 Europe Opioid Use Disorder (OUD) Market Outlook, By 19 to 39 (2020-2028) ($MN)
59 Europe Opioid Use Disorder (OUD) Market Outlook, By 40 to 59 (2020-2028) ($MN)
60 Europe Opioid Use Disorder (OUD) Market Outlook, By Age 60 and over (2020-2028) ($MN)
61 Asia Pacific Opioid Use Disorder (OUD) Market Outlook, By Country (2020-2028) ($MN)
62 Asia Pacific Opioid Use Disorder (OUD) Market Outlook, By Drug Class (2020-2028) ($MN)
63 Asia Pacific Opioid Use Disorder (OUD) Market Outlook, By Methadone (2020-2028) ($MN)
64 Asia Pacific Opioid Use Disorder (OUD) Market Outlook, By Naltrexone (2020-2028) ($MN)
65 Asia Pacific Opioid Use Disorder (OUD) Market Outlook, By Buprenorphine (2020-2028) ($MN)
66 Asia Pacific Opioid Use Disorder (OUD) Market Outlook, By Bunavail (2020-2028) ($MN)
67 Asia Pacific Opioid Use Disorder (OUD) Market Outlook, By Sublocade (2020-2028) ($MN)
68 Asia Pacific Opioid Use Disorder (OUD) Market Outlook, By Suboxone (2020-2028) ($MN)
69 Asia Pacific Opioid Use Disorder (OUD) Market Outlook, By Zubsolv (2020-2028) ($MN)
70 Asia Pacific Opioid Use Disorder (OUD) Market Outlook, By Distribution Channel (2020-2028) ($MN)
71 Asia Pacific Opioid Use Disorder (OUD) Market Outlook, By Retail Pharmacies & Stores (2020-2028) ($MN)
72 Asia Pacific Opioid Use Disorder (OUD) Market Outlook, By Hospitals Pharmacies (2020-2028) ($MN)
73 Asia Pacific Opioid Use Disorder (OUD) Market Outlook, By Online Pharmacies (2020-2028) ($MN)
74 Asia Pacific Opioid Use Disorder (OUD) Market Outlook, By Route of Administration (2020-2028) ($MN)
75 Asia Pacific Opioid Use Disorder (OUD) Market Outlook, By Parenteral (2020-2028) ($MN)
76 Asia Pacific Opioid Use Disorder (OUD) Market Outlook, By Oral (2020-2028) ($MN)
77 Asia Pacific Opioid Use Disorder (OUD) Market Outlook, By Age group (2020-2028) ($MN)
78 Asia Pacific Opioid Use Disorder (OUD) Market Outlook, By 19 to 39 (2020-2028) ($MN)
79 Asia Pacific Opioid Use Disorder (OUD) Market Outlook, By 40 to 59 (2020-2028) ($MN)
80 Asia Pacific Opioid Use Disorder (OUD) Market Outlook, By Age 60 and over (2020-2028) ($MN)
81 South America Opioid Use Disorder (OUD) Market Outlook, By Country (2020-2028) ($MN)
82 South America Opioid Use Disorder (OUD) Market Outlook, By Drug Class (2020-2028) ($MN)
83 South America Opioid Use Disorder (OUD) Market Outlook, By Methadone (2020-2028) ($MN)
84 South America Opioid Use Disorder (OUD) Market Outlook, By Naltrexone (2020-2028) ($MN)
85 South America Opioid Use Disorder (OUD) Market Outlook, By Buprenorphine (2020-2028) ($MN)
86 South America Opioid Use Disorder (OUD) Market Outlook, By Bunavail (2020-2028) ($MN)
87 South America Opioid Use Disorder (OUD) Market Outlook, By Sublocade (2020-2028) ($MN)
88 South America Opioid Use Disorder (OUD) Market Outlook, By Suboxone (2020-2028) ($MN)
89 South America Opioid Use Disorder (OUD) Market Outlook, By Zubsolv (2020-2028) ($MN)
90 South America Opioid Use Disorder (OUD) Market Outlook, By Distribution Channel (2020-2028) ($MN)
91 South America Opioid Use Disorder (OUD) Market Outlook, By Retail Pharmacies & Stores (2020-2028) ($MN)
92 South America Opioid Use Disorder (OUD) Market Outlook, By Hospitals Pharmacies (2020-2028) ($MN)
93 South America Opioid Use Disorder (OUD) Market Outlook, By Online Pharmacies (2020-2028) ($MN)
94 South America Opioid Use Disorder (OUD) Market Outlook, By Route of Administration (2020-2028) ($MN)
95 South America Opioid Use Disorder (OUD) Market Outlook, By Parenteral (2020-2028) ($MN)
96 South America Opioid Use Disorder (OUD) Market Outlook, By Oral (2020-2028) ($MN)
97 South America Opioid Use Disorder (OUD) Market Outlook, By Age group (2020-2028) ($MN)
98 South America Opioid Use Disorder (OUD) Market Outlook, By 19 to 39 (2020-2028) ($MN)
99 South America Opioid Use Disorder (OUD) Market Outlook, By 40 to 59 (2020-2028) ($MN)
100 South America Opioid Use Disorder (OUD) Market Outlook, By Age 60 and over (2020-2028) ($MN)
101 Middle East & Africa Opioid Use Disorder (OUD) Market Outlook, By Country (2020-2028) ($MN)
102 Middle East & Africa Opioid Use Disorder (OUD) Market Outlook, By Drug Class (2020-2028) ($MN)
103 Middle East & Africa Opioid Use Disorder (OUD) Market Outlook, By Methadone (2020-2028) ($MN)
104 Middle East & Africa Opioid Use Disorder (OUD) Market Outlook, By Naltrexone (2020-2028) ($MN)
105 Middle East & Africa Opioid Use Disorder (OUD) Market Outlook, By Buprenorphine (2020-2028) ($MN)
106 Middle East & Africa Opioid Use Disorder (OUD) Market Outlook, By Bunavail (2020-2028) ($MN)
107 Middle East & Africa Opioid Use Disorder (OUD) Market Outlook, By Sublocade (2020-2028) ($MN)
108 Middle East & Africa Opioid Use Disorder (OUD) Market Outlook, By Suboxone (2020-2028) ($MN)
109 Middle East & Africa Opioid Use Disorder (OUD) Market Outlook, By Zubsolv (2020-2028) ($MN)
110 Middle East & Africa Opioid Use Disorder (OUD) Market Outlook, By Distribution Channel (2020-2028) ($MN)
111 Middle East & Africa Opioid Use Disorder (OUD) Market Outlook, By Retail Pharmacies & Stores (2020-2028) ($MN)
112 Middle East & Africa Opioid Use Disorder (OUD) Market Outlook, By Hospitals Pharmacies (2020-2028) ($MN)
113 Middle East & Africa Opioid Use Disorder (OUD) Market Outlook, By Online Pharmacies (2020-2028) ($MN)
114 Middle East & Africa Opioid Use Disorder (OUD) Market Outlook, By Route of Administration (2020-2028) ($MN)
115 Middle East & Africa Opioid Use Disorder (OUD) Market Outlook, By Parenteral (2020-2028) ($MN)
116 Middle East & Africa Opioid Use Disorder (OUD) Market Outlook, By Oral (2020-2028) ($MN)
117 Middle East & Africa Opioid Use Disorder (OUD) Market Outlook, By Age group (2020-2028) ($MN)
118 Middle East & Africa Opioid Use Disorder (OUD) Market Outlook, By 19 to 39 (2020-2028) ($MN)
119 Middle East & Africa Opioid Use Disorder (OUD) Market Outlook, By 40 to 59 (2020-2028) ($MN)
120 Middle East & Africa Opioid Use Disorder (OUD) Market Outlook, By Age 60 and over (2020-2028) ($MN)

List of Figures

RESEARCH METHODOLOGY


Research Methodology

We at Stratistics opt for an extensive research approach which involves data mining, data validation, and data analysis. The various research sources include in-house repository, secondary research, competitor’s sources, social media research, client internal data, and primary research.

Our team of analysts prefers the most reliable and authenticated data sources in order to perform the comprehensive literature search. With access to most of the authenticated data bases our team highly considers the best mix of information through various sources to obtain extensive and accurate analysis.

Each report takes an average time of a month and a team of 4 industry analysts. The time may vary depending on the scope and data availability of the desired market report. The various parameters used in the market assessment are standardized in order to enhance the data accuracy.

Data Mining

The data is collected from several authenticated, reliable, paid and unpaid sources and is filtered depending on the scope & objective of the research. Our reports repository acts as an added advantage in this procedure. Data gathering from the raw material suppliers, distributors and the manufacturers is performed on a regular basis, this helps in the comprehensive understanding of the products value chain. Apart from the above mentioned sources the data is also collected from the industry consultants to ensure the objective of the study is in the right direction.

Market trends such as technological advancements, regulatory affairs, market dynamics (Drivers, Restraints, Opportunities and Challenges) are obtained from scientific journals, market related national & international associations and organizations.

Data Analysis

From the data that is collected depending on the scope & objective of the research the data is subjected for the analysis. The critical steps that we follow for the data analysis include:

  • Product Lifecycle Analysis
  • Competitor analysis
  • Risk analysis
  • Porters Analysis
  • PESTEL Analysis
  • SWOT Analysis

The data engineering is performed by the core industry experts considering both the Marketing Mix Modeling and the Demand Forecasting. The marketing mix modeling makes use of multiple-regression techniques to predict the optimal mix of marketing variables. Regression factor is based on a number of variables and how they relate to an outcome such as sales or profits.


Data Validation

The data validation is performed by the exhaustive primary research from the expert interviews. This includes telephonic interviews, focus groups, face to face interviews, and questionnaires to validate our research from all aspects. The industry experts we approach come from the leading firms, involved in the supply chain ranging from the suppliers, distributors to the manufacturers and consumers so as to ensure an unbiased analysis.

We are in touch with more than 15,000 industry experts with the right mix of consultants, CEO's, presidents, vice presidents, managers, experts from both supply side and demand side, executives and so on.

The data validation involves the primary research from the industry experts belonging to:

  • Leading Companies
  • Suppliers & Distributors
  • Manufacturers
  • Consumers
  • Industry/Strategic Consultants

Apart from the data validation the primary research also helps in performing the fill gap research, i.e. providing solutions for the unmet needs of the research which helps in enhancing the reports quality.


For more details about research methodology, kindly write to us at info@strategymrc.com

Frequently Asked Questions

In case of any queries regarding this report, you can contact the customer service by filing the “Inquiry Before Buy” form available on the right hand side. You may also contact us through email: info@strategymrc.com or phone: +1-301-202-5929

Yes, the samples are available for all the published reports. You can request them by filling the “Request Sample” option available in this page.

Yes, you can request a sample with your specific requirements. All the customized samples will be provided as per the requirement with the real data masked.

All our reports are available in Digital PDF format. In case if you require them in any other formats, such as PPT, Excel etc you can submit a request through “Inquiry Before Buy” form available on the right hand side. You may also contact us through email: info@strategymrc.com or phone: +1-301-202-5929

We offer a free 15% customization with every purchase. This requirement can be fulfilled for both pre and post sale. You may send your customization requirements through email at info@strategymrc.com or call us on +1-301-202-5929.

We have 3 different licensing options available in electronic format.

  • Single User Licence: Allows one person, typically the buyer, to have access to the ordered product. The ordered product cannot be distributed to anyone else.
  • 2-5 User Licence: Allows the ordered product to be shared among a maximum of 5 people within your organisation.
  • Corporate License: Allows the product to be shared among all employees of your organisation regardless of their geographical location.

All our reports are typically be emailed to you as an attachment.

To order any available report you need to register on our website. The payment can be made either through CCAvenue or PayPal payments gateways which accept all international cards.

We extend our support to 6 months post sale. A post sale customization is also provided to cover your unmet needs in the report.

Request Customization

We provide a free 15% customization on every purchase. This requirement can be fulfilled for both pre and post sale. You may send your customization requirements through email at info@strategymrc.com or call us on +1-301-202-5929.

Note: This customization is absolutely free until it falls under the 15% bracket. If your requirement exceeds this a feasibility check will be performed. Post that, a quote will be provided along with the timelines.

WHY CHOOSE US ?

Assured Quality

Assured Quality

Best in class reports with high standard of research integrity

24X7 Research Support

24X7 Research Support

Continuous support to ensure the best customer experience.

Free Customization

Free Customization

Adding more values to your product of interest.

Safe and Secure Access

Safe & Secure Access

Providing a secured environment for all online transactions.

Trusted by 600+ Brands

Trusted by 600+ Brands

Serving the most reputed brands across the world.

Testimonials